Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer

Nature. 2021 Sep;597(7875):E6. doi: 10.1038/s41586-021-03664-3.

Yunhua Liu¹, Xinna Zhang^{2

3}, Cecil Han¹, Guohui Wan¹, Xingxu Huang⁴, Cristina Ivan^{2

3}, Dahai Jiang^{2

3}, Cristian Rodriguez-Aguayo^{3

5}, Gabriel Lopez-Berestein^{3

5}, Pulivarthi H Rao⁶, Dipen M Maru⁷, Andreas Pahl⁸, Xiaoming He⁹, Anil K Sood^{1

2

3}, Lee M Ellis¹⁰, Jan Anderl⁸, Xiongbin Lu^{11

12}

¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gynaecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
⁵ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Paediatrics, Baylor College of Medicine, Houston, TX, USA.
⁷ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Heidelberg Pharma GmbH, Ladenburg, Germany.
⁹ Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
¹⁰ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].
¹² Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].

No abstract available

Publication types